These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 34027681)
1. Transrectal ultrasound features and biopsy outcomes of transition PI-RADS 5. Chung JH; Park BK Acta Radiol; 2022 Apr; 63(4):559-565. PubMed ID: 34027681 [TBL] [Abstract][Full Text] [Related]
2. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225 [TBL] [Abstract][Full Text] [Related]
3. Predictive value of PI-RADS classification in MRI-directed transrectal ultrasound guided prostate biopsy. NiMhurchu E; O'Kelly F; Murphy IG; Lavelle LP; Collins CD; Lennon G; Galvin D; Mulvin D; Quinlan D; McMahon CJ Clin Radiol; 2016 Apr; 71(4):375-80. PubMed ID: 26880299 [TBL] [Abstract][Full Text] [Related]
4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899 [TBL] [Abstract][Full Text] [Related]
5. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798 [TBL] [Abstract][Full Text] [Related]
6. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results. Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003 [TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis. Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878 [TBL] [Abstract][Full Text] [Related]
9. Transrectal ultrasound-guided targeted biopsy of transition zone prostate cancer under cognitive registration with prebiopsy MRI and sonographic findings. Won SY; Cho NH; Choi YD; Park SY Clin Radiol; 2020 Feb; 75(2):157.e21-157.e27. PubMed ID: 31677880 [TBL] [Abstract][Full Text] [Related]
10. New Biopsy Techniques and Imaging Features of Transrectal Ultrasound for Targeting PI-RADS 4 and 5 Lesions. Park BK; Park SY J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32075275 [TBL] [Abstract][Full Text] [Related]
11. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035 [TBL] [Abstract][Full Text] [Related]
12. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy. Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550 [TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772 [TBL] [Abstract][Full Text] [Related]
14. Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Ristau BT; Chen DYT; Ellis J; Malhotra A; DeMora L; Parsons RB; Milestone B; Brody M; Viterbo R; Greenberg R; Smaldone M; Uzzo R; Anaokar J; Kutikov A J Urol; 2018 Apr; 199(4):969-975. PubMed ID: 28988963 [TBL] [Abstract][Full Text] [Related]
15. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318 [TBL] [Abstract][Full Text] [Related]
16. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy. Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117 [TBL] [Abstract][Full Text] [Related]
17. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance. Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389 [TBL] [Abstract][Full Text] [Related]
18. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397 [TBL] [Abstract][Full Text] [Related]
19. Central zone lesions on magnetic resonance imaging: Should we be concerned? Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837 [TBL] [Abstract][Full Text] [Related]
20. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy. Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]